Viveve Medical VIVE shares are trading lower on Thursday, after the company announced that the vive pivotal VIVEVE 2 study did not meet its primary endpoint.
Viveve Medical designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions.
Viveve Medical shares were trading down 26.85% at 63 cents on Thursday. The stock has a 52-week high of $76 and a 52-week low of 54 cents.
Related Link:
Viveve Medical Shares Plummet After Trial Misses Primary Endpoint
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in